Dextromethorphan/bupropion
Combination medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Dextromethorphan/bupropion?
Summarize this article for a 10 year old
Dextromethorphan/bupropion (DXM/BUP), sold under the brand name Auvelity, is a combination medication for the treatment of major depressive disorder (MDD).[1] Its active components are dextromethorphan (DXM) and bupropion.[1] Patients who stayed on the medication had an average of 11% greater reduction in depressive symptoms than placebo in an FDA approval trial.[2][3] It is taken as a tablet by mouth.[1]
Combination of | |
---|---|
Dextromethorphan | NMDA receptor antagonist, σ1 receptor agonist, serotonin-norepinephrine reuptake inhibitor, nicotinic acetylcholine receptor negative allosteric modulator, and other actions |
Bupropion | Norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor negative allosteric modulator |
Clinical data | |
Trade names | Auvelity |
Other names | DXM/BUP; AXS-05 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Side effects of dextromethorphan/bupropion include dizziness, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, and hyperhidrosis, among others.[1] The mechanism of action of dextromethorphan/bupropion in the treatment of depression is unknown.[1]
Dextromethorphan/bupropion was developed by Axsome Therapeutics and was approved for the treatment of major depressive disorder in the United States in August 2022.[1]